Takeda Announces Candidates for New Directors after the Transition to a Company with Audit and Supervisory

May 10, 2016

Osaka, Japan, May 10, 2016 --- Takeda Pharmaceutical Company Limited (TSE 4502) today announced that it has decided the candidates for new Directors which will be proposed to the 140th Ordinary General Meeting of Shareholders on June 29, 2016. Takeda previously announced to change its corporate governance system to a Company with Audit and Supervisory if the transition is approved by the shareholders' meeting. The candidates are as follows;

1. Candidates for Non-Audit and Supervisory Committee Directors

Name	Category		Current Role
Yasuchika Hasegawa	Internal	Existing	Director, Chairman of the Board
Christophe Weber	Internal	Existing	Representative Director, President & Chief Executive Officer
Shinji Honda	Internal	Existing	Senior Managing Director, Corporate Strategy Officer
Masato Iwasaki	Internal	Existing	Director, President, Japan Pharma Business Unit
Andrew Plump	Internal	Existing	Director, Chief Medical & Scientific Officer
Fumio Sudo	Outside	Existing	Outside Director
Masahiro Sakane	Outside	Existing	Outside Director
Michel Orsinger	Outside	New	(Former head of Global Orthopedics Group, Depuy Synthes Companies, Johnson & Johnson)
Toshiyuki Shiga	Outside	New	(Vice- Chairman, Nissan Motor Co., Ltd.)
Emiko Higashi	Outside	New	(Managing Director, Tomon Partners, LLC)
Yoshiaki Fujimori	Outside	New	(Director, Representative Executive Officer, President and CEO, LIXIL Group Corporation)

2. Candidates for Audit and Supervisory Committee Directors

Name	Category		Current Role
Yasuhiko Yamanaka	Internal	New	Corporate Auditor
Shiro Kuniya	Outside	New	Outside Corporate Auditor
Koji Hatsukawa	Outside	New	(Certified Public Accountant)
Jean-Luc Butel	Outside	New	(Global Healthcare Advisor, President, K8 Global Pte. Ltd.)

Media Contact

Tsuyoshi Tada

Tel: +81-3-3278-2417

Email: [email protected]

###